Giuseppe Tonini

Full Professor of Medical Oncology

Campus Bio Medico University Hospital
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (46)

Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7

Year:

2026

Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).

Year:

2025

Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on any diabetes medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), patients not receiving diabetes medications: 17.5 months (95%CI: 14.2 – 26.6; 77 events). B) Progression Free Survival NSCLC matched cohort; patients on any diabetes medication: 7.9 months (95%CI: 5.4 – 10.8; 113 events), patients not receiving diabetes medications: 10.1 months (95%CI: 7.7 – 13.8; 99 events). C) Overall Survival Melanoma matched cohort; patients on any diabetes medication: 22.9 months (95%CI: 12.0 – NR; 25 events), patients not receiving diabetes medications: NR months (95%CI: 28.8 – NR; 52 events). D) Progression Free Survival Melanoma matched cohort; patients on any diabetes medication: 11.4 months (95%CI: 4.9 – 23.4; 37 events), patients not receiving diabetes medications: 13.8 months (95%CI: 8.7 – 26.0; 77 events). NR: not reached; PSM: propensity score matching.

Year:

2025

Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:2, caliper 0.1).

Year:

2025

Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).

Year:

2025

Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.

Year:

2025

Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes medications/insulin therapy only, and metformin therapy (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving diabetes medications: 18.9 months (95%CI: 15.9-21.6; 684 events), patients on other diabetes medications/insulin therapy only: 19.3 months (95%CI: 11.6-22.9; 48 events), patients on metformin: 12.3 months (95%CI: 9.8-15.9; 100 events). B) Progression Free Survival whole cohort; patients not receiving diabetes medications: 8.2 months (95%CI: 7.1-9.4; 872 events), patients on other diabetes medications/insulin therapy only: 10.7 months (95%CI: 6.7-11.6; 61 events), patients on metformin: 7.9 months (95%CI: 5.1-10.1; 124 events).

Year:

2025

Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival whole cohort; patients on more than one diabetes medications: 15.5 months (95%CI: 11.1-20.6; 79 events), patients on one medication: 12.5 months (95%CI: 10.0 – 18.9; 69 events), patients not receiving diabetes medications: 18.9 months (95%CI: 15.9 – 21.5; 684 events). B) Progression Free Survival whole cohort; patients on more than one diabetes medications: 7.9 months (95%CI: 6.2-11.4; 101 events), patients on one medication: 8.4 months (95%CI: 4.9 – 11.9; 84 events), patients not receiving diabetes medications: 8.2 months (95%CI: 7.1 – 9.4; 872 events). Polypharmacy: more than one diabetes medication.

Year:

2025

Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).

Year:

2025

NSCLC cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:1, caliper 0.1).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (37)

Fabio Puglisi

Head of the Unit of Medical Oncology and Cancer Prevention

-

ITALY
View details

Valentina Guarneri

Associate Professor

University of Padova

ITALY
View details

Maurizio Simmaco

Full Professor Molecular Biology - Director Diparmet Diagnostic sciences

Sapienza University of Rome

ITALY
View details

Umberto Malapelle

-

ITALY
View details

Edoardo Crimini

Medical Oncologist

European Institute of Oncology

ITALY
View details

Marco Gaetano Tucci

Associate Professor

University of Bari

ITALY
View details

David J. Pinato

Imperial College London

UNITED KINGDOM
View details

Bruno Vincenzi

Professor of Medical Oncology

Università Campus Bio-Medico

ITALY
View details

Giuseppe Giannini

Head, Unit of Advanced Molecular Diagnostic in Oncology

Sapienza University

ITALY
View details

Maria Grazia Vitale

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Armando Orlandi

Università Cattolica del Sacro Cuore

ITALY
View details

Lucia Del Mastro

dirigente medico

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro

ITALY
View details

Sebastiano Buti

Ricercatore a contratto tipo B

University of Parma

ITALY
View details

Andrea DeCensi

Director

Champalimaud Foundation

PORTUGAL
View details

Lorenzo Nibid

Campus Bio Medico University Hospital

ITALY
View details

Giancarlo Pruneri

University of Milan

ITALY
View details

Marco Ferrari

Associate Professor

University of Padova

ITALY
View details

Alessio Cortellini

Imperial College London

UNITED KINGDOM
View details

Maria Giuseppa Vitale

-

ITALY
View details

Giuseppe Curigliano

European Institute of Oncology

ITALY
View details

Lidia Strigari

Head of Department

IRCCS Azienda Ospedaliero-Universitaria di Bologna

ITALY
View details

Alberto Zambelli

Associate Professor

University of Milano-Bicocca

ITALY
View details

Paolo Marchetti

Sapienza University of Rome

ITALY
View details

SIMONA PISEGNA

Sapienza University of Rome

ITALY
View details

Michele Ghidini

Docenti di ruolo di IIa fascia

University of Insubria

ITALY
View details

Francesco Pantano

National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale a Professore di I Fascia) in Hematology, Oncology and Rheumatology (MED 06/D3)

Ministero dell’Istruzione, dell’Università e della Ricerca

ITALY
View details

Antonio Avallone

Chief of DH Chemotherapy

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Sara Lonardi

Head of Dept

Istituto Oncologico Veneto

ITALY
View details

Melissa Bersanelli

Adjunct Professor in Medical Oncology

University of Parma

ITALY
View details

olga nigro

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Alessandro Russo

Humanitas University

ITALY
View details

MICHELE DE TURSI

ASSOCIATE PROFESSOR

University "G. d'Annunzio"

ITALY
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

PIERFRANCO CONTE

Professore di 1^ fascia

University of Padova

ITALY
View details

Chiara Cremolini

University Hospital of Pisa

ITALY
View details

Giuseppe Perrone

Università Campus Bio-Medico di Roma

ITALY
View details

Antonio D'Alessio

King's College Hospital

UNITED KINGDOM
View details